Patient characteristics
| Patient groups . | Description . | N . | Study entry* . | |
|---|---|---|---|---|
| HIV RNA median copies/mL (range) . | CD4 median cells/μL (range) . | |||
| Primary HIV infection | ||||
| Fiebig stage I-II | HIV RNA positive, antibody negative within 14 d prior to study entry, and ART naive | 15 | 457 679 (4 381-2 000 000) | 431 (285-1679) |
| Fiebig stage III-IV | HIV RNA positive, ELISA positive, Western blot negative, or indeterminate within 31-120 d prior to study entry, and ART naive | 7 | 27 789 (754-2 850 000) | 634 (426-1032) |
| Fiebig stage V-VI | HIV RNA positive, ELISA positive, Western blot positive within 31-120 d prior to study entry, and ART naive | 38 | 19 632 (25-3 560 000) | 543 (294-1074) |
| Controls | ||||
| Uninfected (U) | 14 | |||
| High risk (HR) | Men who have sex with men (MSM) age-matched to the PHIV subjects who had engaged in risk behavior within 6 mo prior to study entry | 14 | ||
| Early established infection (E) | Diagnosed > 1 y but < 2 y and ART naive | 6 | 29 140 (4040-86 202) | 373 (247-682) |
| Chronic/untreated (CU) | Diagnosed > 1 y but < 5 y and ART naive | 9 | 6 850 (615-20 000) | 301 (244-858) |
| Chronic/treated (CT) | ART > 1 y | 9 | < 50 | 669 (427-1056) |
| Long-term nonprogressors (LTNP) | Diagnosed > 10 y and ART naive with detectable viremia | 8 | 6 388 (81-34 100) | 625 (298-752) |
| Elite controllers (EC) | Diagnosed > 10 y and ART naive with undetectable viremia | 6 | < 50 | 702 (584-1650) |
| Patient groups . | Description . | N . | Study entry* . | |
|---|---|---|---|---|
| HIV RNA median copies/mL (range) . | CD4 median cells/μL (range) . | |||
| Primary HIV infection | ||||
| Fiebig stage I-II | HIV RNA positive, antibody negative within 14 d prior to study entry, and ART naive | 15 | 457 679 (4 381-2 000 000) | 431 (285-1679) |
| Fiebig stage III-IV | HIV RNA positive, ELISA positive, Western blot negative, or indeterminate within 31-120 d prior to study entry, and ART naive | 7 | 27 789 (754-2 850 000) | 634 (426-1032) |
| Fiebig stage V-VI | HIV RNA positive, ELISA positive, Western blot positive within 31-120 d prior to study entry, and ART naive | 38 | 19 632 (25-3 560 000) | 543 (294-1074) |
| Controls | ||||
| Uninfected (U) | 14 | |||
| High risk (HR) | Men who have sex with men (MSM) age-matched to the PHIV subjects who had engaged in risk behavior within 6 mo prior to study entry | 14 | ||
| Early established infection (E) | Diagnosed > 1 y but < 2 y and ART naive | 6 | 29 140 (4040-86 202) | 373 (247-682) |
| Chronic/untreated (CU) | Diagnosed > 1 y but < 5 y and ART naive | 9 | 6 850 (615-20 000) | 301 (244-858) |
| Chronic/treated (CT) | ART > 1 y | 9 | < 50 | 669 (427-1056) |
| Long-term nonprogressors (LTNP) | Diagnosed > 10 y and ART naive with detectable viremia | 8 | 6 388 (81-34 100) | 625 (298-752) |
| Elite controllers (EC) | Diagnosed > 10 y and ART naive with undetectable viremia | 6 | < 50 | 702 (584-1650) |
Subjects were analyzed at study entry.